Figure 5.
Cutaneous melanoma patients benefit from immune checkpoint blockade therapy better than non-cutaneous melanoma patients. Created with BioRender.com.
Cutaneous melanoma patients benefit from immune checkpoint blockade therapy better than non-cutaneous melanoma patients. Created with BioRender.com.